Pharma News in Global Health and Sustainability

Published on: 

PTSM: Pharmaceutical Technology Sourcing and Management

PTSM: Pharmaceutical Technology Sourcing and Management-08-07-2013, Volume 9, Issue 8

A roundup of developments in global health and sustainability from the bio/pharmaceutical industry, its suppliers, and other public and private organizations.

GlaxoSmithKline (GSK) and Save the Children have launched a $1- million Healthcare Innovation Award to identify and reward innovations in healthcare which have proven successful in reducing child deaths in developing countries. From June 27 to August 26, 2013, organizations from across the developing world can nominate examples of innovative healthcare approaches they have discovered or implemented. These approaches must have resulted in tangible improvements to under-age-five child survival rates, be sustainable, and have the potential to be scaled-up and replicated. Co-chaired by Sir Andrew Witty, CEO of GSK, and Justin Forsyth, CEO of Save the Children, the judging anel, made up of experts from the fields of public health, science and academia, will award $250,000 to the best healthcare innovation to further progress their work. An additional $750,000 is available for runners-up awards. The award will also provide a platform for winning organizations to showcase their innovations and share information to enable others with an interest in improving healthcare to adapt and replicate successful interventions and create more positive change for children in their own country and beyond.

Sanofi and GDF SUEZ, an energy firm, have signed an agreement to strengthen their collaboration for implementing projects in the field of energy at Sanofi industrial sites. The five-year contract includes mainly renewable energy production and distribution systems. Building on an initial agreement signed in March 2012 for Europe and Turkey, the two groups have expanded their collaboration to include sites in the United States, Canada, Mexico, Brazil, China, and Singapore. All Sanofi’s production lines will be included: chemicals, pharmaceuticals, vaccines, biotechnology, and animal health. The initial three-year term contract is extended to five years.